Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Reversible histone acetylation is one of the key mechanisms involved in the epigenetic control of gene expression. A variety of recent studies has revealed a role for acetylation in a much broader repertoire of physiological processes, including proliferation control and protein folding, and has highlighted how a variety of non-histone regulatory proteins are influenced by acetylation. Inhibition of histone deacetylase (HDAC) prompts tumour cells to enter apoptosis and, as a consequence, several HDAC inhibitors have entered clinical trials. It is likely that HDAC inhibitor drugs will provide an important class of new mechanism-based therapeutics for cancer.

Original publication

DOI

10.1016/j.coph.2006.03.010

Type

Journal article

Journal

Curr Opin Pharmacol

Publication Date

08/2006

Volume

6

Pages

369 - 375

Keywords

Animals, Antineoplastic Agents, Drug Therapy, Combination, Enzyme Inhibitors, Histone Deacetylase Inhibitors, Histone Deacetylases, Humans, Neoplasms